ConKay Medical Systems, a Pleasanton, CA-based medtech company, raised $1.8M in Seed funding.
Backers included Unorthodox Ventures, SCP Ventures, WS Investment Company, and individual angel investors.
The company intends to use the funds to expand operations and development efforts.
Led by Founder and CEO Albert Yuan, ConKay Medical Systems is an early-stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure. Its catheter is adjustable and tackles all the current limitations, including avoiding pacemaker leads. Without the need to open a patient’s chest, the device mimics open heart surgery by leaving a minimal implant around the annulus of the valve.
Commenting on the news, Albert Yuan said: “Millions of Tricuspid Regurgitation patients worldwide are currently left with no medical options and at ConKay, our mission is to help patients live longer lives with their loved ones. We are grateful to our investors for their trust and support in helping us achieve this goal.”
The company anticipated raises its next round of financing in the 2nd quarter of 2024 to support First-in-Human testing.
FinSMEs
18/03/2024